Andrew J Murtha
Overview
Explore the profile of Andrew J Murtha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
205
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fonseca N, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha A, et al.
Nat Commun
. 2024 Feb;
15(1):1828.
PMID: 38418825
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification...
2.
Warner E, Van der Eecken K, Murtha A, Kwan E, Herberts C, Sipola J, et al.
Nat Cancer
. 2024 Jan;
5(1):114-130.
PMID: 38177459
De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely collected tissue has hindered genomic stratification and precision oncology. Here, we leveraged a rare study of surgical...
3.
Fonseca N, Van der Eecken K, Herberts C, Verbeke S, Ng S, Lumen N, et al.
JCO Precis Oncol
. 2022 May;
6:e2100543.
PMID: 35507889
Purpose: Pulmonary involvement is rare in metastatic hormone-sensitive prostate cancer (mHSPC) that recurs after treatment for localized disease. Guidelines recommend intensive systemic therapy, similar to patients with liver metastases, but...
4.
Lavoie J, Vandekerkhove G, Murtha A, Wang G, Wyatt A, Eigl B
Urol Case Rep
. 2021 Jul;
39:101762.
PMID: 34258232
The management of metastatic urothelial cancer is rapidly evolving since immune checkpoint inhibitors were introduced. We present the case of a patient with metastatic upper tract urothelial cancer who had...
5.
Vandekerkhove G, Lavoie J, Annala M, Murtha A, Sundahl N, Walz S, et al.
Nat Commun
. 2021 Jan;
12(1):184.
PMID: 33420073
Molecular stratification can improve the management of advanced cancers, but requires relevant tumor samples. Metastatic urothelial carcinoma (mUC) is poised to benefit given a recent expansion of treatment options and...
6.
Warner E, Herberts C, Fu S, Yip S, Wong A, Wang G, et al.
Clin Cancer Res
. 2021 Jan;
27(6):1650-1662.
PMID: 33414135
Purpose: DNA damage repair (DDR) defects are common across cancer types and can indicate therapeutic vulnerability. Optimal exploitation of DDR defects in prostate cancer requires new diagnostic strategies and a...
7.
Herberts C, Murtha A, Fu S, Wang G, Schonlau E, Xue H, et al.
Eur Urol
. 2020 May;
78(6):834-844.
PMID: 32451180
Background: Activating mutations in AKT1 and PIK3CA are undercharacterised in metastatic castration-resistant prostate cancer (mCRPC), but are linked to activation of phosphatidylinositol 3-kinase (PI3K) signalling and sensitivity to pathway inhibitors...
8.
Ritch E, Fu S, Herberts C, Wang G, Warner E, Schonlau E, et al.
Clin Cancer Res
. 2019 Nov;
26(5):1114-1125.
PMID: 31744831
Purpose: DNA mismatch repair defects (MMRd) and tumor hypermutation are rare and under-characterized in metastatic prostate cancer (mPC). Furthermore, because hypermutated MMRd prostate cancers can respond to immune checkpoint inhibitors,...